Article: Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus

Aim Of The Study: Aim of the study is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype.

Material And Methods: The study included 27 patients according to inclusion criteria. Main laboratory studies were performed in all patients at the baseline and during the treatment.

Results: Efficacy of the antiviral therapy was assessed by measuring the SVR12 and the SVR24 along with measuring of viral load during the treatment. The SVR12 and SVR24 rate was 100% (27/27).

Discussion: The results of the treatment were comparable to the results of pivotal, large-scale, randomized clinical trials. There were no serious adverse events during the treatment.

Citing Articles

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy.

Flisiak R, Zarebska-Michaluk D, Janczewska E, Lapinski T, Rogalska M, Karpinska E Cancers (Basel). 2021; 13(15).

PMID: 34359594 PMC: 8345092. DOI: 10.3390/cancers13153694.

References

1.

Zeuzem S, Jacobson I, Baykal T, Marinho R, Poordad F, Bourliere M . Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1604-14. DOI: 10.1056/NEJMoa1401561. View

2.

Nakano T, Lau G, Lau G, Sugiyama M, Mizokami M . An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2011; 32(2):339-45. DOI: 10.1111/j.1478-3231.2011.02684.x. View

3.

Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts S . Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat. 2017; 24(11):936-943. DOI: 10.1111/jvh.12722. View

4.

Feld J, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y . Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2015; 64(2):301-307. DOI: 10.1016/j.jhep.2015.10.005. View

5.

Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K . Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016; 44(9):946-956. DOI: 10.1111/apt.13790. View

6.

Westbrook R, Dusheiko G . Natural history of hepatitis C. J Hepatol. 2014; 61(1 Suppl):S58-68. DOI: 10.1016/j.jhep.2014.07.012. View

7.

Thrift A, El-Serag H, Kanwal F . Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2016; 14(2):122-132. DOI: 10.1038/nrgastro.2016.176. View

8.

Welzel T, Asselah T, Dumas E, Zeuzem S, Shaw D, Hazzan R . Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol. 2017; 2(7):494-500. DOI: 10.1016/S2468-1253(17)30071-7. View

9.

Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D . Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1594-603. DOI: 10.1056/NEJMoa1315722. View

10.

Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K . ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21):1973-82. DOI: 10.1056/NEJMoa1402869. View

11.

Kohli A, Alshati A, Georgie F, Manch R, Gish R . Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therap Adv Gastroenterol. 2016; 9(6):887-897. PMC: 5076774. DOI: 10.1177/1756283X16665254. View

Ombitasvir/paritaprevir/ritonavir + Dasabuvir ± Ribavirin for Treatment of Chronic Hepatitis C 1 Genotype in the Republic of Belarus